ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 436

Baseline Anemia As a Predictor of Radiographic Progression in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analyses from Two Phase 3 Trials

Burkhard Moeller1, Axel Finckh2, Godehard Scholz1, Harry Shi3, Carol A Connell4 and Sander Strengholt5, 1Department for Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland, 2University Hospital of Geneva, Geneva, Switzerland, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, Capelle aan den IJssel, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Anemia, joint damage, rheumatoid arthritis (RA) and tofacitinib

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Session Title: Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Anemia in patients with rheumatoid arthritis (RA) can help to identify those with more rapid erosive disease.1,2 Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In this post hoc analysis, we explored whether anemia was a predictor of radiographic progression in patients with RA who were treated with tofacitinib.

Methods: Data were from two 24-month, Phase 3 randomized controlled trials in methotrexate (MTX)-naïve (ORAL Start [NCT01039688]) or MTX-inadequate responder (IR) patients (ORAL Scan [NCT00847613]). Patients received either tofacitinib 5 or 10 mg twice daily (as monotherapy or with background MTX), placebo or MTX. Radiographic progression was evaluated by modified Total Sharp Score (mTSS) at baseline (BL), Month (M)6, M12, and M24. Anemia was defined as lower normal hemoglobin limits of 12 g/dL for women or 13 g/dL for men. We used a linear mixed model with repeated measure analysis to analyze the impact of BL anemia on change in radiographic joint damage (ΔmTSS), adjusting for treatment, age, gender, disease duration, and BL mTSS, autoantibody status, DAS28, corticosteroid, and non-steroidal anti-inflammatory drug (NSAID) use. Analyses were performed on observed data without linear extrapolation on missing data.

Results: Anemia was present at BL in 312/956 MTX-naïve patients (32.6%), RA duration ranged from 2.7–3.4 (mean) and from 0.7–0.8 (median) years, and in 321/797 MTX-IR patients (40.3%), RA duration ranged from 8.9–9.2 (mean) and from 6.0–7.7 (median) years. In MTX-naïve patients, anemia at BL was significantly associated with additional ΔmTSS from BL to M6 only (difference in ΔmTSS with and without BL anemia = 0.40; p<0.001) and increased ΔmTSS was also observed at M6 for patients receiving tofacitinib (0.25; p<0.05) or MTX monotherapy (0.95; p<0.005) (Figure 1A). There were no differences in ΔmTSS observed at M12 or M24 for either treatment group according to anemia status (data not shown). No associations between BL anemia and ΔmTSS were observed for MTX-IR patients overall or in either treatment group at M6 (Figure 1B), M12, or M24.

Conclusion: BL anemia was associated with radiographic progression at M6 in MTX-naïve patients, regardless of treatment received (tofacitinib or MTX monotherapy) but not at later time points (M12/M24). These data support the evidence that anemia at BL is a predictive parameter for joint damage progression in MTX-naïve patients, at least up to M6.

References:

   1.   Moller B et al. Ann Rheum Dis 2014; 73: 691-696.

   2.   van Steenbergen HW et al. Ann Rheum Dis 2013; 72: e16.

Figure 1. Association between baseline anemia and change in radiographic progression at Month 6 in A) MTX-naïve and B) MTX-IR patients


Disclosure: B. Moeller, None; A. Finckh, AbbVie, 8,A2BIO, 8,BMS, 8,Eli-Lilly, 8,MSD, 8,Pfizer Inc, 8,Roche, 8; G. Scholz, None; H. Shi, Pfizer Inc, 1,Pfizer Inc, 3; C. A. Connell, Pfizer Inc, 1,Pfizer Inc, 3; S. Strengholt, Pfizer Inc, 1,Pfizer Inc, 3.

To cite this abstract in AMA style:

Moeller B, Finckh A, Scholz G, Shi H, Connell CA, Strengholt S. Baseline Anemia As a Predictor of Radiographic Progression in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analyses from Two Phase 3 Trials [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/baseline-anemia-as-a-predictor-of-radiographic-progression-in-tofacitinib-treated-rheumatoid-arthritis-patients-post-hoc-analyses-from-two-phase-3-trials/. Accessed May 26, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-anemia-as-a-predictor-of-radiographic-progression-in-tofacitinib-treated-rheumatoid-arthritis-patients-post-hoc-analyses-from-two-phase-3-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.